J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study

Johnson & Johnson (NYSE:JNJ) announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study.

Head-to-head comparison data versus AstraZeneca Plc‘s (NASDAQ:AZN) Tagrisso (osimertinib) showed Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended OS in the first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations.

Also Read: Pharmaceutical Firms Say UK Investment Is ‘Unlikely’ Unless Payment Levy Is Addressed

Johnson & Johnson said in a Wednesday press release that the median OS is ...